Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Placebos, active control groups, and the unpredictability paradox.

K M Mattocks1, R I Horwitz

  • 1Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06520-8056, USA.

Biological Psychiatry
|April 22, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gender difference in prognosis after transient cerebral ischemia or minor stroke.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2015
Same author

Association between comorbidity and clinical characteristics of MS.

Acta neurologica Scandinavica·2010
Same author

Boosting enrollment in neurology trials with Local Identification and Outreach Networks (LIONs).

Neurology·2009
Same author

Estrogen after ischemic stroke: clinical basis and design of the Women's Estrogen for Stroke Trial.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2007
Same author

Impaired insulin sensitivity among nondiabetic patients with a recent TIA or ischemic stroke.

Neurology·2003
Same author

Use of Ephedra-containing products and risk for hemorrhagic stroke.

Neurology·2003

Active control groups won't decrease negative randomized controlled trials. Addressing patient heterogeneity in clinical trials through better classification can reduce contradictory results and improve treatment response rates.

Area of Science:

  • Clinical Trials
  • Psychiatric Research
  • Medical Ethics

Background:

  • Randomized controlled trials (RCTs) frequently use placebo controls to assess treatment efficacy.
  • Increasingly, RCTs face scrutiny due to high rates of negative outcomes and ethical concerns regarding placebo use.
  • A debate exists on replacing placebo controls with active controls in psychiatric research.

Purpose of the Study:

  • To evaluate the impact of replacing placebo controls with active controls on the number of negative trials.
  • To identify underlying factors contributing to variability and contradiction in RCT results.
  • To propose strategies for reducing negative trial outcomes in clinical research.

Main Methods:

  • The study critically examines the argument for replacing placebo controls with active controls.

Related Experiment Videos

  • It analyzes the role of clinical heterogeneity in influencing RCT outcomes.
  • The authors suggest enhanced patient characterization as a method to address heterogeneity.

    • Main Results:

    • The preferential use of active control groups is unlikely to decrease the number of negative trials.
    • Clinical heterogeneity in patient characteristics, disease severity, comorbidity, and cotherapies significantly contributes to inconsistent trial results.
    • Improved disease taxonomies, severity indices, and comorbidity classifications are proposed as solutions.

    Conclusions:

    • Shifting to active controls alone will not resolve the issue of negative trials.
    • Reducing clinical heterogeneity by better characterizing patients is crucial for improving the reliability of RCTs.
    • Enhanced patient classification can lead to more consistent treatment and control response rates, thus reducing negative trial findings.